학술논문
FOLFIRI Plus Durvalumab with or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial
Document Type
Article
Author
Tougeron, D.; Dahan, L.; Evesque, L.; Le Malicot, K.; Lepage, C.; El Hajbi, F.; Aparicio, T.; Bouché, O.; Bonichon Lamichhane, N.; Chibaudel, B.; Angelergues, A.; Bodere, A.; Phelip, J.-M.; Mabro, M.; Kaluzinski, L.; Petorin, C.; Breysacher, G.; Rinaldi, Y.; Zaanan, A.; Smith, D.; Gouttebel, M.-C.; Perret, C.; Etchepare, N.; Emile, J.-F.; Sanfourche, I.; Di Fiore, F.; Artru, P.; Louvet, C.
Source
In: JAMA Oncology . (JAMA Oncology, 2024)
Subject
Language
English
ISSN
23742445
23742437
23742437